☰

Jason J. Zoeller, Ph.D. - Publications

Affiliations: 
2009 Thomas Jefferson University, Philadelphia, PA, United States 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

17/33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Caswell-Jin JL, McNamara KL, Dering J, Chen H, Dichmann R, Perez A, Patel R, Kotler E, Zoeller JJ, Brugge JS, Press MF, Slamon DJ, Curtis C, Hurvitz SA. Abstract P4-07-01: Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-07-01  0.324
2020 Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Fujita M, Welm AL, Letai A, Leverson JD, Blot V, Bronson RT, Dillon DA, Brugge JS. Abstract P3-11-06: Pre-clinical assessment of combined ABT-263/Navitoclax and ABT-414 or ABBV-321 treatment for EGFR-expressing TNBC Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-11-06  0.315
2019 Zoeller JJ, Vagodny A, Taneja K, Tan BY, O'Brien N, Slamon DJ, Sampath D, Leverson JD, Bronson RT, Dillon DA, Brugge JS. Neutralization of BCL-2/XL enhances the cytotoxicity of T-DM1 in vivo. Molecular Cancer Therapeutics. PMID 30962322 DOI: 10.1158/1535-7163.Mct-18-0743  0.314
2019 Zoeller JJ, Hurvitz SA, Press MF, Selfors LM, Dering J, Slamon DJ, Brugge JS. Abstract 2978: Clinical evaluation of lapatinib induced BCL-2 adaptive responses Cancer Research. 79: 2978-2978. DOI: 10.1158/1538-7445.Sabcs18-2978  0.31
2018 Rosenbluth JM, Schackmann R, Li C, Sachs N, Dillon D, Richardson A, Brock J, Garber J, Gray GK, Zoeller J, Boedicker M, Kuiken HJ, Clevers H, Brugge J. Abstract 989: Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages and can form chimeric mammary glands in vivo Cancer Research. 78: 989-989. DOI: 10.1158/1538-7445.Am2018-989  0.306
2014 Neill T, Zoeller J. Matrix biology highlights. Matrix Biology. 48: 1-2. PMID 26603526 DOI: 10.1016/J.Matbio.2015.11.002  0.316
2012 Zoeller JJ, Bronson RT, Gilmer TM, Selfors LM, Lu Y, Mills GB, Brugge JS. Abstract P4-08-05: Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo. Cancer Research. 72: 4834-4834. DOI: 10.1158/0008-5472.Sabcs12-P4-08-05  0.379
2012 Schnaar R, Paulson JC, Macauley MS, Nycholat C, Pfrengle F, Rademacher C, Mahan A, Dionne K, Suscovich T, Alter G, Katoh T, Kiwamoto T, Brummet M, Bochner B, Tiemeyer M, ... ... Zoeller J, et al. Program and abstracts for the 2012 Joint Meeting of the Society for Glycobiology & American Society for Matrix Biology Glycobiology. 22: 1518-1650. DOI: 10.1093/Glycob/Cws127  0.449
2011 Brugge J, Muranen T, Zoeller J, Worster D, Iwanicki M, Selfors L, Mills G. DL1-1: Adaptive Resistance to Targeted Therapies. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Dl1-1  0.303
2009 San Antonio JD, Zoeller JJ, Habursky K, Turner K, Pimtong W, Burrows M, Choi S, Basra S, Bennett JS, DeGrado WF, Iozzo RV. A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis. The American Journal of Pathology. 175: 1338-47. PMID 19700757 DOI: 10.2353/Ajpath.2009.090234  0.556
2009 Iozzo RV, Zoeller JJ, Nyström A. Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Molecules and Cells. 27: 503-13. PMID 19466598 DOI: 10.1007/S10059-009-0069-0  0.528
2009 Zoeller JJ, Whitelock JM, Iozzo RV. Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biology : Journal of the International Society For Matrix Biology. 28: 284-91. PMID 19422911 DOI: 10.1016/J.Matbio.2009.04.010  0.555
2009 Zoeller JJ, Pimtong W, Corby H, Goldoni S, Iozzo AE, Owens RT, Ho SY, Iozzo RV. A central role for decorin during vertebrate convergent extension. The Journal of Biological Chemistry. 284: 11728-37. PMID 19211552 DOI: 10.1074/Jbc.M808991200  0.486
2008 Zoeller JJ, McQuillan A, Whitelock J, Ho SY, Iozzo RV. A central function for perlecan in skeletal muscle and cardiovascular development. The Journal of Cell Biology. 181: 381-94. PMID 18426981 DOI: 10.1083/Jcb.200708022  0.501
2008 Zoeller JJ, Iozzo RV. Proteomic profiling of endorepellin angiostatic activity on human endothelial cells. Proteome Science. 6: 7. PMID 18269764 DOI: 10.1186/1477-5956-6-7  0.533
2006 Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur ML, Barker CA, Camphausen K, Iozzo RV. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. Journal of the National Cancer Institute. 98: 1634-46. PMID 17105986 DOI: 10.1093/Jnci/Djj441  0.513
2006 BIX G, BURROWS M, CASTELLO R, ZOELLER J, IOZZO R, CARDI C, THAKUR M, IOZZO R. Actin' Up: Endorepellin and endothelial morphogenesis Matrix Biology. 25: S58-S58. DOI: 10.1016/J.Matbio.2006.08.160  0.493
Low-probability matches (unlikely to be authored by this person)
2016 Zoeller JJ, Bronson RT, Sampath D, Leverson J, Brugge JS. Abstract P4-14-02: Neutralization of BCL2/BCL-XL enhances the cytotoxicity of T-DM1 in vivo Cancer Research. 76: 4358-4358. DOI: 10.1158/1538-7445.Sabcs15-P4-14-02  0.287
2017 Zoeller JJ, Bronson RT, Selfors LM, Mills GB, Brugge JS. Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. Npj Breast Cancer. 3: 18. PMID 28649658 DOI: 10.1038/s41523-017-0020-z  0.264
2020 McNamara KL, Caswell-Jin JL, Ma Z, Zoeller JJ, Kriner M, Zhou Z, Reeves J, Hoang M, Beechem J, Slamon DJ, Press MF, Brugge J, Hurvitz SA, Curtis C. Abstract P4-10-12: Characterizing the tumor and immune microenvironment through treatment to predict response to neoadjuvant HER2-targeted therapy using the Digital Spatial Profiler Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-10-12  0.262
2013 Hurvitz S, Miller J, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Dering J, ... ... Zoeller J, et al. Abstract S1-02: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07) Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S1-02  0.242
2017 Wang Y, Woehrstein JB, Donoghue N, Dai M, Avendano MS, Schackmann RCJ, Zoeller J, Wang SSH, Tillberg PW, Park D, Lapan SW, Boyden ES, Brugge JS, Kaeser PS, Church G, et al. Rapid sequential in situ multiplexing with DNA-Exchange-Imaging in Neuronal Cells and Tissues. Nano Letters. PMID 28933153 DOI: 10.1021/Acs.Nanolett.7B02716  0.235
2022 Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications. 13: 3022. PMID 35641483 DOI: 10.1038/s41467-022-30568-1  0.219
2021 Zoeller JJ, Press MF, Selfors LM, Dering J, Slamon DJ, Hurvitz SA, Brugge JS. Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. Plos One. 16: e0251163. PMID 33951110 DOI: 10.1371/journal.pone.0251163  0.207
2005 Patel NA, Zoeller J, Stamper DL, Fujimoto JG, Brezinski ME. Monitoring osteoarthritis in the rat model using optical coherence tomography. Ieee Transactions On Medical Imaging. 24: 155-9. PMID 15707241 DOI: 10.1109/Tmi.2004.839360  0.205
2015 Neill T, Zoeller J. Makin' sense of the antisense: HA expression and synthesis requires HAS2-AS1 and O-GlcNAcylation. Matrix Biology. 41: 1. PMID 25645084 DOI: 10.1016/J.Matbio.2015.01.006  0.195
2017 Zoeller JJ, Bronson RT, Selfors LM, Mills GB, Brugge JS. Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. Npj Breast Cancer. 3: 38. PMID 28948214 DOI: 10.1038/s41523-017-0031-9  0.189
2021 Daniels VW, Zoeller JJ, van Gastel N, McQueeney KE, Parvin S, Potter DS, Fell GG, Ferreira VG, Yilma B, Gupta R, Spetz J, Bhola PD, Endress JE, Harris IS, Carrilho E, et al. Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. Science Signaling. 14. PMID 34103421 DOI: 10.1126/scisignal.abc7405  0.187
2021 McNamara KL, Caswell-Jin JL, Joshi R, Ma Z, Kotler E, Bean GR, Kriner M, Zhou Z, Hoang M, Beechem J, Zoeller J, Press MF, Slamon DJ, Hurvitz SA, Curtis C. Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nature Cancer. 2: 400-413. PMID 34966897 DOI: 10.1038/s43018-021-00190-z  0.181
2020 Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, et al. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nature Communications. 11: 5824. PMID 33203854 DOI: 10.1038/s41467-020-19494-2  0.167
2020 Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS, Fujita M, Welm AL, Letai A, Leverson JD, Blot V, Bronson RT, Dillon DA, Brugge JS. Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Research : Bcr. 22: 132. PMID 33256808 DOI: 10.1186/s13058-020-01374-8  0.162
2015 Neill T, Zoeller J. Matrix Biology highlights. Matrix Biology : Journal of the International Society For Matrix Biology. 40: 1-4. PMID 25497903 DOI: 10.1016/j.matbio.2014.11.002  0.094
2014 Neill T, Zoeller J. Matrix biology highlights. Matrix Biology : Journal of the International Society For Matrix Biology. 33: 1-4. PMID 24559886 DOI: 10.1016/j.matbio.2014.01.008  0.094
Hide low-probability matches.